On October 16-20, 2023, the 20th General Membership Meeting of the Reproductive Health Supplies Coalition (RHSC) was held in Accra, the capital of Ghana, Africa. Li Xiaoyu, Vice President and Secretary General of the China Reproductive Health Industry Association, was invited to lead a delegation to attend the conference. WALT’s gynecological tumor early screening products made a wonderful appearance, providing Chinese solutions for reproductive health.
Reproduction is a fundamental characteristic of life, and reproductive health is an eternal theme of human well-being and social development. Reproductive health is one of the core contents of China’s population health strategy, which is related to the sustainable development of China’s economy and society, and is related to the happiness and harmony of families.
With the improvement of economic and living standards, the acceleration of pace of life and the tremendous increase in survival pressures, unhealthy lifestyles and women’s special physiological structures in recent years, the incidence and mortality of gynecological tumors in China have been increasing year by year and trending towards younger ages. Among them, the incidence of cervical cancer ranks second among female reproductive system malignancies. Endometrial cancer ranks third among female reproductive system malignancies in China, while it ranks first in developed countries, which has posed a serious threat to women’s health.
Based on gene methylation technology, WALT has developed an endometrial cancer exfoliated cell methylation detection kit – IUterusureTM, and a cervical cancer exfoliated cell methylation detection kit – ICervsureTM. It provides a non-invasive, convenient, accurate and early screening method for people at risk of endometrial cancer and cervical cancer.
IUterusureTM, is an auxiliary diagnosis of early endometrial cancer by detecting the promoter methylation levels of the UCECM19* and UCECM22* genes of cervical exfoliated cells.
ICervsureTM can be used for triage of HPV-positive populations to clarify the significance of ASCUS (Atypical Squamous Cells of Undetermined Significance) detection, judge whether LSIL (Low-grade Squamous Intraepithelial Lesion) patients have disease progression, and guide patients in choosing the timing of disease diagnosis and surgical treatment, reducing the burden on the healthcare system.
The General Membership Meeting was co-hosted by the Reproductive Health Supplies Coalition (RHSC) and the Ministry of Health of Ghana, attracting high-level decision makers, researchers, authoritative experts, project managers, opinion leaders and youth representatives from member organizations around the world to participate in the conference. It aims to share and discuss the latest research findings and practical experience in the field of reproductive health, and work out strategies to improve the accessibility of high-quality reproductive health products globally. During the meeting, a themed forum entitled “From China to the World – Reflections on the Development of China’s Reproductive Health Industry” was held concurrently to build a platform for external exchanges, tell China’s stories, introduce excellent reproductive health products from China, and jointly explore solutions to the difficulties in exporting products.
